HUP0105407A3 - Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates - Google Patents

Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates

Info

Publication number
HUP0105407A3
HUP0105407A3 HU0105407A HUP0105407A HUP0105407A3 HU P0105407 A3 HUP0105407 A3 HU P0105407A3 HU 0105407 A HU0105407 A HU 0105407A HU P0105407 A HUP0105407 A HU P0105407A HU P0105407 A3 HUP0105407 A3 HU P0105407A3
Authority
HU
Hungary
Prior art keywords
triazolo
intermediates
preparation
pharmaceutical compositions
quinolin derivatives
Prior art date
Application number
HU0105407A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Priority to HU0105407A priority Critical patent/HUP0105407A3/hu
Priority to CA2470064A priority patent/CA2470064C/en
Priority to EP02788260A priority patent/EP1456204A1/en
Priority to KR1020047009789A priority patent/KR100934796B1/ko
Priority to PL02370747A priority patent/PL370747A1/xx
Priority to YU56004A priority patent/RS56004A/sr
Priority to CNB028256468A priority patent/CN1307175C/zh
Priority to AU2002353240A priority patent/AU2002353240B2/en
Priority to BR0215276-2A priority patent/BR0215276A/pt
Priority to HR20040672A priority patent/HRP20040672A2/xx
Priority to UA20040706067A priority patent/UA79955C2/uk
Priority to JP2003554684A priority patent/JP4724366B2/ja
Priority to US10/499,250 priority patent/US7365089B2/en
Priority to NZ534016A priority patent/NZ534016A/en
Priority to IL16244402A priority patent/IL162444A0/xx
Priority to MXPA04006113A priority patent/MXPA04006113A/es
Priority to PCT/HU2002/000143 priority patent/WO2003053968A1/en
Priority to HU0402282A priority patent/HUP0402282A3/hu
Priority to MEP-188/08A priority patent/MEP18808A/xx
Priority to EA200400848A priority patent/EA007066B1/ru
Publication of HUP0105407D0 publication Critical patent/HUP0105407D0/hu
Publication of HUP0105407A2 publication Critical patent/HUP0105407A2/hu
Publication of HUP0105407A3 publication Critical patent/HUP0105407A3/hu
Priority to MA27724A priority patent/MA27094A1/fr
Priority to TNP2004000106A priority patent/TNSN04106A1/en
Priority to IL162444A priority patent/IL162444A/en
Priority to IS7318A priority patent/IS7318A/is
Priority to ZA200404802A priority patent/ZA200404802B/en
Priority to NO20043119A priority patent/NO329757B1/no
Priority to US12/039,272 priority patent/US7713992B2/en
Priority to JP2010200550A priority patent/JP2011042653A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
HU0105407A 2001-12-21 2001-12-21 Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates HUP0105407A3 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
HU0105407A HUP0105407A3 (en) 2001-12-21 2001-12-21 Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
PCT/HU2002/000143 WO2003053968A1 (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
MXPA04006113A MXPA04006113A (es) 2001-12-21 2002-12-17 Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.
KR1020047009789A KR100934796B1 (ko) 2001-12-21 2002-12-17 아데노신 수용체 리간드로서 유용한 트리아졸로-퀴놀린유도체
PL02370747A PL370747A1 (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
YU56004A RS56004A (sr) 2001-12-21 2002-12-17 Derivati triazolo-kvinolina korisni kao veznici receptora adenozina
CNB028256468A CN1307175C (zh) 2001-12-21 2002-12-17 用作腺苷受体配体的三唑并喹啉衍生物
AU2002353240A AU2002353240B2 (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
BR0215276-2A BR0215276A (pt) 2001-12-21 2002-12-17 Derivados de triazolo-quinolina úteis como ligandos receptores de adenosina
HR20040672A HRP20040672A2 (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
UA20040706067A UA79955C2 (en) 2001-12-21 2002-12-17 Triazolochinoline derivatives as ligands of adenosine receptors
JP2003554684A JP4724366B2 (ja) 2001-12-21 2002-12-17 アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体
US10/499,250 US7365089B2 (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
NZ534016A NZ534016A (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
IL16244402A IL162444A0 (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
CA2470064A CA2470064C (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
HU0402282A HUP0402282A3 (en) 2001-12-21 2002-12-17 Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
EP02788260A EP1456204A1 (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
MEP-188/08A MEP18808A (en) 2001-12-21 2002-12-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands
EA200400848A EA007066B1 (ru) 2001-12-21 2002-12-17 Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов
MA27724A MA27094A1 (fr) 2001-12-21 2004-06-07 Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine.
TNP2004000106A TNSN04106A1 (en) 2001-12-21 2004-06-08 Triazolo-quinolin derivatives useful as adenosine receptor ligands
IL162444A IL162444A (en) 2001-12-21 2004-06-10 Triazolo-quinolin derivatives useful as adenosine receptor ligands
IS7318A IS7318A (is) 2001-12-21 2004-06-16 Tríasól-kínólínafleiður sem eru gagnlegar sem adenósínviðtakabindlar
ZA200404802A ZA200404802B (en) 2001-12-21 2004-06-17 Triazolo-quinolin derivatives useful as adenosine receptor ligands.
NO20043119A NO329757B1 (no) 2001-12-21 2004-07-20 Triazolokinolinderivater som kan anvendes som adenosinreseptorligander, fremgangsmate for fremstilling derav, mellomprodukter i fremgangsmaten, farmasoytiske preparater som inneholder forbindelsene og anvendelse av forbindelsene til fremstilling av farmasoytiske preparater
US12/039,272 US7713992B2 (en) 2001-12-21 2008-02-28 Triazolo-quinolin derivatives useful as adenosine receptor ligands
JP2010200550A JP2011042653A (ja) 2001-12-21 2010-09-08 アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0105407A HUP0105407A3 (en) 2001-12-21 2001-12-21 Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates

Publications (3)

Publication Number Publication Date
HUP0105407D0 HUP0105407D0 (en) 2003-02-28
HUP0105407A2 HUP0105407A2 (hu) 2003-10-28
HUP0105407A3 true HUP0105407A3 (en) 2004-04-28

Family

ID=90001529

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0105407A HUP0105407A3 (en) 2001-12-21 2001-12-21 Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HU0402282A HUP0402282A3 (en) 2001-12-21 2002-12-17 Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0402282A HUP0402282A3 (en) 2001-12-21 2002-12-17 Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them

Country Status (23)

Country Link
US (2) US7365089B2 (enExample)
EP (1) EP1456204A1 (enExample)
JP (2) JP4724366B2 (enExample)
KR (1) KR100934796B1 (enExample)
CN (1) CN1307175C (enExample)
AU (1) AU2002353240B2 (enExample)
BR (1) BR0215276A (enExample)
CA (1) CA2470064C (enExample)
EA (1) EA007066B1 (enExample)
HR (1) HRP20040672A2 (enExample)
HU (2) HUP0105407A3 (enExample)
IL (2) IL162444A0 (enExample)
IS (1) IS7318A (enExample)
MA (1) MA27094A1 (enExample)
MX (1) MXPA04006113A (enExample)
NO (1) NO329757B1 (enExample)
NZ (1) NZ534016A (enExample)
PL (1) PL370747A1 (enExample)
RS (1) RS56004A (enExample)
TN (1) TNSN04106A1 (enExample)
UA (1) UA79955C2 (enExample)
WO (1) WO2003053968A1 (enExample)
ZA (1) ZA200404802B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
HUP0400812A2 (en) * 2004-04-19 2006-02-28 Sanofi Aventis Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
JP2008504294A (ja) * 2004-06-25 2008-02-14 アムジエン・インコーポレーテツド サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
CN102702312A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdvyigsk、制备和应用
CN102702314A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdfyigsr、制备和应用
CN102702313A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdvyigsr、制备和应用
CN102702315A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdsyigsk、制备和应用
CN102702316A (zh) * 2006-11-30 2012-10-03 首都医科大学 具有靶向抗血栓活性的rgdfyigsk、制备和应用
HUP0700395A2 (en) * 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
BR122021012629B1 (pt) 2013-02-01 2022-06-07 Wellstat Therapeutics Corporation Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
CN108358927B (zh) * 2018-01-26 2020-09-01 郑州大学 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用
BR112023011284A2 (pt) 2020-12-09 2024-02-06 Wellstat Therapeutics Corp Composto de imidazoquinolina com atividade anti-inflamatória, antifúngica, antiparasítica e antineoplásica
CN119302957B (zh) * 2023-07-14 2025-11-21 同济大学 三唑并喹啉衍生物在制备预防或治疗疟疾的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE280110C (enExample)
DE280109C (enExample)
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
DD280110A1 (de) * 1989-02-22 1990-06-27 Univ Berlin Humboldt Verfahren zur herstellung von 1.2.4-triazolo/1.5-a/-pyridin-8-carbonitrilen
DD280109A1 (de) * 1989-02-22 1990-06-27 Univ Berlin Humboldt Verfahren zur herstellung substituierter 1.2.4-triazolo/1.5-a/-pyridine
DE3926770A1 (de) * 1989-08-12 1991-02-14 Basf Ag (1,2,4)triazolo(1,5-a)pyridine
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates

Also Published As

Publication number Publication date
HRP20040672A2 (en) 2005-08-31
NO20043119L (no) 2004-07-20
ZA200404802B (en) 2005-08-29
US20050124648A1 (en) 2005-06-09
HUP0105407A2 (hu) 2003-10-28
CN1606556A (zh) 2005-04-13
BR0215276A (pt) 2004-12-14
IS7318A (is) 2004-06-16
AU2002353240B2 (en) 2008-06-19
EP1456204A1 (en) 2004-09-15
KR100934796B1 (ko) 2009-12-31
US20080146604A1 (en) 2008-06-19
US7365089B2 (en) 2008-04-29
EA007066B1 (ru) 2006-06-30
NO329757B1 (no) 2010-12-13
JP2011042653A (ja) 2011-03-03
EA200400848A1 (ru) 2004-12-30
US7713992B2 (en) 2010-05-11
AU2002353240A1 (en) 2003-07-09
IL162444A (en) 2010-04-29
WO2003053968A1 (en) 2003-07-03
HUP0402282A3 (en) 2007-12-28
TNSN04106A1 (en) 2006-06-01
HUP0402282A2 (hu) 2005-02-28
NZ534016A (en) 2005-04-29
HUP0105407D0 (en) 2003-02-28
CA2470064A1 (en) 2003-07-03
JP2005518384A (ja) 2005-06-23
JP4724366B2 (ja) 2011-07-13
KR20040072671A (ko) 2004-08-18
CN1307175C (zh) 2007-03-28
RS56004A (sr) 2006-10-27
IL162444A0 (en) 2005-11-20
PL370747A1 (en) 2005-05-30
MA27094A1 (fr) 2004-12-20
MXPA04006113A (es) 2005-06-08
UA79955C2 (en) 2007-08-10
CA2470064C (en) 2010-01-26

Similar Documents

Publication Publication Date Title
HUP0401292A3 (en) Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
HUP0204410A3 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
IL161693A0 (en) N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
HUP0200207A3 (en) Substituted 2-aryl-3-(hetroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compositions and methods for their preparation
HUP0401083A3 (en) 4-amino-6-phenyl-pyrrolo [2,3-d] pyrimidine derivatives, pharmaceutical compositions containing them and process for the preparation of the compounds
HUP0202103A3 (en) 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives, their use, pharmaceutical compositions containing them, process for the preparation of the compounds and intermediates
IL191960A (en) History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them
HUP0203052A3 (en) Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0104762A3 (en) Pharmaceutical moxifloxacin compositions and process for their preparation
HUP0003826A3 (en) Novel triazolo [4,5-b] pyrimidine derivatives, process for their preparation and pharmaceutical compositions thereof
HUP0203140A3 (en) Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0204563A3 (en) Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions
IL176385A (en) Compressed history of pyrrolo [34, -c] carbazol-1-van and pyrrolo [34, -c] carbazol-3,1-discussion and pharmaceutical preparations containing them
IL147248A0 (en) Naphthyridine derivatives, process for their preparation, their use and pharmaceutical compositions comprising them
HUP0105054A3 (en) Imidazo[4,5-c]-pyridine-4-on-derivatives, pharmaceutical compositions containing them and process for their preparation
HUP0402282A3 (en) Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0202624A3 (en) Pyrazolo[4,3-d]pyrimidine-derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0105132A3 (en) Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions
HUP0400317A3 (en) Beta-carboline derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0003118A3 (en) Use of 2,7-substituted octahydro-1h-pyrido [1,2-a]pyrazine derivatives for production of pharmaceutical compositions
HUP0103075A3 (en) Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one derivatives and intermediates thereof
HUP0105406A3 (en) Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0202282A3 (en) Novel octahydro-2h-pyrido[1,2-a]pyrazine compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished